Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 |
| clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05353907 | Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma(DECIMA) | not yet recruiting | — | 78 | Guy's and St Thomas' NHS Foundation TrustOTHER | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05181501 | A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | not yet recruiting | Phase 1 | 20 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04702932 | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies(GEN-HEMO-INF) | not yet recruiting | — | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04338386 | Detection and Pathogenesis of Novel Protein F | not yet recruiting | — | 100 | Wuhan Asia Heart HospitalOTHER | 0 | Apr 10, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03966443 | Fluciclovine PET/CT in Multiple Myeloma Patients(FLUCIPET) | recruiting | — | 10 | Oslo University HospitalOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT02869555 | Institut Paoli Calmettes Multiple Myeloma Database | recruiting | — | 5,000 | Institut Paoli-CalmettesOTHER | 1 | Aug 17, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Oct 12, 2022source: clinicaltrials